Shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Free Report) are scheduled to reverse split on Thursday, November 19th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, November 18th.
Scinai Immunotherapeutics Price Performance
NASDAQ:SCNI opened at $0.40 on Friday. The stock has a market capitalization of $540,000.00, a PE ratio of 0.05 and a beta of 2.27. Scinai Immunotherapeutics has a 1-year low of $0.39 and a 1-year high of $13.00. The firm has a fifty day simple moving average of $1.09 and a 200 day simple moving average of $4.04. The company has a current ratio of 1.23, a quick ratio of 1.35 and a debt-to-equity ratio of 0.06.
Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of ($8.50) by $8.80. The firm had revenue of $1.86 million for the quarter, compared to analyst estimates of $0.49 million.
Wall Street Analyst Weigh In
Separately, Weiss Ratings upgraded shares of Scinai Immunotherapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. One analyst has rated the stock with a Sell rating. According to MarketBeat, Scinai Immunotherapeutics has an average rating of “Sell”.
View Our Latest Stock Analysis on Scinai Immunotherapeutics
Scinai Immunotherapeutics Company Profile
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects. Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.
Read More
- Five stocks we like better than Scinai Immunotherapeutics
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
- 3 GARP Plays That Could Offer a Better Balance as Markets Turn Volatile
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
